Medicare

The Effect of the March Health Legislation on Prescription Drug Prices
November 4, 2010pdf
Letter to the Honorable Paul Ryan

Patient Protection and Affordable Care Act
November 18, 2009pdfadditional infoblog post
Cost estimate for the amendment in the nature of a substitute to H.R. 3590, as proposed in the Senate on November 18, 2009

H.R. 3962, Affordable Health Care for America Act
November 5, 2009pdfblog post
Cost estimate for the bill as introduced on October 29, 2009, incorporating the manager's amendment from November 3, 2009

H.R. 3962, Affordable Health Care for America Act
November 4, 2009pdfblog post
Cost estimate for the amendment in the nature of a substitute as introduced on November 3, 2009

House Tri-Committee Health Reform Discussion Draft
July 8, 2009pdf
Preliminary analysis of the Medicare component of the health reform discussion draft posted on the Web site of the House Committee on Education and Labor on June 19, 2009

An Assessment of the Potential Effects of the Reductions in Medicare's Payment Rates for Physicians Called for Under Current Law
March 27, 2009pdf
Letter to the Honorable John M. Spratt Jr.

Key Issues in Analyzing Major Health Insurance Proposals
December 2008htmlpdfchartsblog post

Budget Options, Volume 1: Health Care
December 2008pdfchartsblog post

The Long-Term Budgetary Effects of Three Specified Policy Scenarios
March 14, 2008htmlpdfblog post
Letter to the Honorable John M. Spratt Jr.

Estimated Changes in Net Federal Outlays from Alternative Proposals for Changing Physician Payment Rates
March 2008pdf

Additional Information on Medicare Advantage Provisions of the CHAMP Act
October 10, 2007pdf
Letter to the Honorable Jim McCrery

Estimate of the Budgetary Impact of Section 651 of H.R. 3162, the Children's Health and Medicare Protection Act of 2007
August 17, 2007pdf
Letter to the Honorable Sam Johnson

Information on Bids by Medicare Advantage Plans
August 17, 2007pdf
Letter to the Honorable John M. Spratt Jr.

Background Paper: The Impact of Medicare's Payment Rates on the Volume of Services Provided by Skilled Nursing Facilities
July 2007pdf

Testimony on the Medicare Advantage Program
June 28, 2007htmlpdfwebcast
Testimony before the Committee on the Budget, U.S. House of Representatives

Medicare Advantage: Private Health Plans in Medicare
June 28, 2007htmlpdf

Testimony on Health Care and the Budget: Issues and Challenges for Reform
June 21, 2007htmlpdfwebcast
Testimony before the Committee on the Budget, United States Senate

Testimony on Research on the Comparative Effectiveness of Medical Treatments: Options for an Expanded Federal Role
June 12, 2007htmlpdf
Testimony before the Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives

Background Paper: Factors Underlying the Growth in Medicare's Spending for Physicians' Services
June 2007pdf

S. 1082, Prescription Drug User Fee Amendments of 2007
April 27, 2007pdf
Cost estimate for the bill as reported by the Senate Committee on Health, Education, Labor, and Pensions on April 24, 2007

Medicare Advantage Statistics by State
April 17, 2007pdf
Letter to the Honorable Ron Wyden

Effects of Medicare's Drug Pricing on Other Purchasers
April 16, 2007pdf
Letter to the Honorable Debbie Stabenow

S. 3, Medicare Prescription Drug Price Negotiation Act of 2007
April 16, 2007pdf
Cost estimate for the bill as reported by the Senate Committee on Finance on April 13, 2007

Testimony on the Medicare Advantage Program: Enrollment Trends and Budgetary Effects
April 11, 2007pdfwebcast
Testimony before the Committee on Finance, United States Senate

Issues Regarding Drug Price Negotiation in Medicare
April 10, 2007pdf
Letter to the Honorable Ron Wyden

Testimony on the Medicare Advantage Program: Trends and Options
March 21, 2007htmlpdf
Testimony before the Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives

Potential Effects of Disclosing Price Rebates on the Medicare Drug Benefit
March 12, 2007pdf
Letter to the Honorable Joe Barton and the Honorable Jim McCrery

Testimony on Medicare's Payments to Physicians: Options for Changing the Sustainable Growth Rate
March 1, 2007pdfwebcast
Testimony before the Committee on Finance, United States Senate

Detailed Projections for Medicare, Medicaid, and State Children's Health Insurance Program
March 2007pdf

H.R. 4, Medicare Prescription Drug Price Negotiation Act of 2007
January 10, 2007htmlpdf
Cost estimate for the bill as introduced on January 5, 2007.

Designing a Premium Support System for Medicare
December 2006pdf

The Sustainable Growth Rate Formula for Setting Medicare's Physician Payment Rates
September 7, 2006pdf

Testimony on Medicare's Physician Payment Rates and the Sustainable Growth Rate
July 25, 2006pdf
Testimony before the Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives

Estimate of the Budgetary Impact of Extending the Initial Enrollment Period for the Medicare Prescription Drug Benefit (Part D of Medicare)
May 1, 2006pdf
Letter to the Honorable Fortney Pete Stark

The Long-Term Budget Outlook
December 2005pdfadditional info

High-Cost Medicare Beneficiaries
May 2005htmlpdf

Table of Estimates of Proposals to Revise Medicare Payments for Physicians' Services
March 2005pdf

Updated Estimates of Spending for the Medicare Prescription Drug Program
March 4, 2005htmlpdf
Letter to the Honorable Joe Barton

Projection of Spending for the Medicare Part D Benefit
February 9, 2005htmlpdf
Letter to the Honorable William "Bill" M. Thomas

CBO's Analysis of Regional Preferred Provider Organizations Under the Medicare Modernization Act
October 2004htmlpdf

A Detailed Description of CBO's Cost Estimate for the Medicare Prescription Drug Benefit
July 2004htmlpdf

Testimony on Medicare's Physician Fee Schedule
May 5, 2004htmlpdf
Testimony before the Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives

Would Prescription Drug Importation Reduce U.S. Drug Spending?
April 29, 2004htmlpdf

Testimony on Estimating the Cost of the Medicare Modernization Act
March 24, 2004htmlpdf
Testimony before the Committee on Ways and Means, U.S. House of Representatives

Authority to Negotiate Prices for Single-Source Drugs for Medicare Beneficiaries
March 3, 2004htmlpdf
Letter to the Honorable Ron Wyden

Comparison of CBO and Administration Estimates of the Effect of H.R. 1 on Direct Spending
February 2, 2004htmlpdf
Letter to the Honorable Jim Nussle

Estimate of the Effect of Striking the "Noninterference" Provision as Added by P.L. 108-173, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
January 23, 2004htmlpdf
Letter to the Honorable William H. Frist, M.D.

Letter to the Honorable Ted Stevens regarding H.R. 1, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003
November 20, 2003htmlpdf

H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act of 2003
November 20, 2003htmlpdf
Cost estimate for the bill conference agreement

Letter to the Honorable Don Nickles providing additional information about CBO's cost estimate for the conference agreement on H.R. 1
November 20, 2003htmlpdf

H.R. 2427, Pharmaceutical Market Access Act of 2003
November 19, 2003htmlpdf
Cost estimate for the bill as passed by the U.S. House of Representatives on July 25, 2003

Medicare Beneficiaries Who Receive Health Insurance Provided by Employers
November 14, 2003htmlpdf
Letter to the Honorable William "Bill" M. Thomas

Letter to the Honorable Orrin G. Hatch regarding S. 1, the Prescription Drug and Medicare Improvement Act of 2003
August 27, 2003htmlpdf

H.R. 1, Medicare Prescription Drug and Modernization Act of 2003
July 22, 2003htmlpdf
Cost estimate for the bill as passed by the House of Representatives on June 27, 2003

S. 1, Prescription Drug and Medicare Improvement Act of 2003
July 22, 2003htmlpdf
Cost estimate for the bill as passed by the Senate on June 27, 2003, with a modification requested by Senate conferees

H.R. 1, Medicare and Prescription Drug Moderization Act of 2003
June 26, 2003htmlpdf
Cost estimate for the democratic amendment to H.R. 1.

H.R. 1, Medicare Prescription Drug and Modernization Act of 2003
June 25, 2003htmlpdf
Cost estimate for the bill as introduced by the Committee on Rules on June 25, 2003.

S. 1, Prescription Drug and Medicare Improvement Act of 2003, as reported by the Committee on Finance, and incorporating subsequent changes provided by the committee on June 17, 2003
June 18, 2003htmlpdf
Cost estimate for the bill as reported by the Committee on Finance, and incorporating subsequent changes provided by the committee on June 17, 2003

S. 1, Prescription Drug and Medicare Improvement Act of 2003
June 17, 2003htmlpdf
Cost estimate for the bill as reported by the Committee on Finance on June 13, 2003

Testimony on Prescription Drug Coverage and Medicare's Fiscal Challenges
April 9, 2003htmlpdf
Testimony before the Committee on Ways and Means, U.S. House of Representatives

Testimony on the Medicare Challenge: It's Not Just About Prescription Drugs
March 20, 2003htmlpdf
Testimony before the Special Committee on Aging, United States Senate

Projected spending for prescription drugs by and on behalf of Medicare enrollees
February 3, 2003htmlpdf

Memo regarding projected spending for prescription drugs by and on behalf of Medicare enrollees
February 2003htmlpdf

Issues in Designing a Prescription Drug Benefit for Medicare
October 2002htmlpdf

Letter to the Honorable W. J. "Billy" Tauzin regarding H.R. 4954, the Medicare Modernization and Prescription Drug Act of 2002
September 24, 2002htmlpdf

Testimony on Disease Management in Medicare: Data Analysis and Benefit Design Issues
September 19, 2002htmlpdf
Testimony before the Special Committee on Aging, United States Senate

Letter to the Honorable William "Bill" M. Thomas regarding CBO's cost estimate for H.R. 4954, the Medicare Modernization and Prescription Drug Act of 2002
July 27, 2002htmlpdf

Preliminary cost estimate of S. 812 as Modified by the Edwards-Collins Amendment
July 2002htmlpdf

Medicare Modernization and Prescription Drug Act of 2002 (As Approved by the Energy and Commerce Committee)
June 24, 2002htmlpdf
Cost estimate for the bill as ordered reported by the House Committee on Energy and Commerce on June 21, 2002

H.R. 4954, Medicare Modernization and Prescription Drug Act of 2002 (As Approved by the Ways and Means Committee)
June 24, 2002htmlpdf
Cost estimate for the bill as ordered reported by the House Committee on Ways and Means on June 19, 2002

Preliminary Cost Estimates of the Effects on Direct Spending of Establishing a Prescription Drug Benefit in Medicare
April 2002pdf

Testimony on Projections of Medicare and Prescription Drug Spending
March 7, 2002htmlpdf
Testimony before the Committee on Finance, U.S. Senate

S. 754, Drug Competition Act of 2001
February 1, 2002htmlpdf
Cost estimate for the bill as ordered reported by the Senate Committee on the Judiciary on October 18, 2001

Letter to the Honorable Michael Bilirakis regarding CBO's estimate of the costs of a prescription drug benefit in Medicare
August 10, 2001htmlpdf

Letter to the Honorable Max Baucus regarding updated estimates of the direct spending effects of four proposals from the 106th Congress for a prescription drug benefit in Medicare (Tables 1 and 5 corrected 08/10/2001)
June 11, 2001htmlpdf

Testimony on Medicare Reform: Providing Prescription Drug Coverage for Seniors
May 16, 2001pdf
Testimony before the Committee on Energy and Commerce, Subcommittee on Health, U.S. House of Representatives

Testimony on Laying the Groundwork for a Medicare Prescription Drug Benefit
March 27, 2001htmlpdf
Testimony before the Committee on Ways and Means, Subcommittee on Health, U.S. House of Representatives

Testimony on Prescription Drugs and Medicare Financing
March 22, 2001htmlpdf
Testimony before the Committee on Finance, United States Senate

Letter to the Honorable Frank R. Lautenberg regarding the assumptions underlying CBO's estimates of proposals for a Medicare prescription drug benefit
September 1, 2000htmlpdf

Testimony on a CBO Analysis of the Administration's Prescription Drug Proposal
May 11, 2000htmlpdf
Testimony before the Subcommittee on Health, Committee on Ways and Means, U.S. House of Representatives

How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry
July 1998htmlpdf

How the Medicaid Rebate on Prescription Drugs Affects Pricing in the Pharmaceutical Industry
January 1996htmlpdf